Araújo Renatha A, Sales Nathali A A, Basile Roberta C, Feringer-Junior Walter H, Apparício Maricy, Ferraz Guilherme C, Queiroz-Neto Antonio
Laboratory of Equine Exercise Physiology and Pharmacology (LAFEQ), Department of Animal Morphology and Physiology, School of Agricultural and Veterinary Studies, São Paulo State University, FCAV/UNESP, Via de Acesso Prof. Paulo D. Castellane s/n., Jaboticabal 14884-900, SP, Brazil.
Department of Veterinary Medicine, Metropolitan University of Santos, UNIMES, Av. Gen. Francisco Glicério, 8, Santos 11045-002, SP, Brazil.
Vet Sci. 2023 Aug 22;10(9):531. doi: 10.3390/vetsci10090531.
Firocoxib is a non-steroidal anti-inflammatory drug specifically formulated for veterinary medicine and selectively acts on inhibiting the cyclooxygenase 2 enzyme (COX-2). This study evaluated the possible adverse effects of administering oral therapeutic firocoxib on gastric mucosa, hematological parameters, coagulation cascade, and hepatic and renal biochemistry in healthy horses. Nine clinically healthy Arabian horses, approximately 9 years old, received 0.1 mg/kg of oral firocoxib for 14 days. The gastroscopic examination was conducted 1 day before starting treatment (D0) and two days after the last blood collection (D23). Venous blood samples were obtained for laboratory tests on day 1, immediately prior to the initiation of treatment (D1), after 7 and 14 days of treatment (D7 and D14), and 7 days after the conclusion of treatment (D21. No changes were found in the gastroscopic and hematological tests. Coagulation and serum biochemistry levels remain between these species' average values. However, the increased activated partial thromboplastin time (aPTT) and prothrombin time (PT) indicate reduced blood coagulation capacity, which contradicts the expected effect of treatment with selective COX-2 inhibitors, as these drugs theoretically promote coagulation. Administering firocoxib to horses is safe as it does not cause significant adverse reactions. Therefore, it is a suitable option for managing inflammatory conditions in these animals with attention to an unexpected adverse anti-coagulopathy effect, and further study is warranted.
非甾体抗炎药，专门为兽医学配制，选择性地作用于抑制环氧化酶2（COX-2）。本研究评估了口服治疗剂量的非甾体抗炎药对健康马匹胃黏膜、血液学参数、凝血级联反应以及肝脏和肾脏生化指标的潜在不良影响。9匹临床健康的阿拉伯马，年龄约9岁，接受0.1mg/kg的口服非甾体抗炎药，持续14天。在开始治疗前1天（D0）和最后一次采血后2天（D23）进行胃镜检查。在治疗第1天（即治疗开始前，D1）、治疗7天和14天后（D7和D14）以及治疗结束后7天（D21）采集静脉血样进行实验室检测。胃镜和血液学检测未发现变化。凝血和血清生化水平保持在这些物种的平均值之间。然而，活化部分凝血活酶时间（aPTT）和凝血酶原时间（PT）增加表明血液凝固能力下降，这与选择性COX-2抑制剂治疗的预期效果相矛盾，因为这些药物理论上会促进凝血。给马使用非甾体抗炎药是安全的，因为它不会引起明显的不良反应。因此，在注意到意外的抗凝不良反应的情况下，它是治疗这些动物炎症性疾病的合适选择，值得进一步研究。
